These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37574809)

  • 41. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
    Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
    Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer.
    Cheng YW; Pincas H; Bacolod MD; Schemmann G; Giardina SF; Huang J; Barral S; Idrees K; Khan SA; Zeng Z; Rosenberg S; Notterman DA; Ott J; Paty P; Barany F
    Clin Cancer Res; 2008 Oct; 14(19):6005-13. PubMed ID: 18829479
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
    Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
    PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach.
    Loh M; Liem N; Vaithilingam A; Lim PL; Sapari NS; Elahi E; Mok ZY; Cheng CL; Yan B; Pang B; Salto-Tellez M; Yong WP; Iacopetta B; Soong R
    BMC Gastroenterol; 2014 Mar; 14():55. PubMed ID: 24674026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
    Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
    Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
    Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
    Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intermediate- and low-methylation epigenotypes do not correspond to CpG island methylator phenotype (low and -zero) in colorectal cancer.
    Karpinski P; Walter M; Szmida E; Ramsey D; Misiak B; Kozlowska J; Bebenek M; Grzebieniak Z; Blin N; Laczmanski L; Sasiadek MM
    Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):201-8. PubMed ID: 23175427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.
    Weisenberger DJ; Siegmund KD; Campan M; Young J; Long TI; Faasse MA; Kang GH; Widschwendter M; Weener D; Buchanan D; Koh H; Simms L; Barker M; Leggett B; Levine J; Kim M; French AJ; Thibodeau SN; Jass J; Haile R; Laird PW
    Nat Genet; 2006 Jul; 38(7):787-93. PubMed ID: 16804544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers.
    Olaru AV; Cheng Y; Agarwal R; Yang J; David S; Abraham JM; Yu W; Kwon JH; Lazarev M; Brant SR; Marohn MR; Hutcheon DF; Harpaz N; Meltzer SJ; Mori Y
    Inflamm Bowel Dis; 2012 Apr; 18(4):641-8. PubMed ID: 21830278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
    Jia M; Jansen L; Walter V; Tagscherer K; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
    Br J Cancer; 2016 Nov; 115(11):1359-1366. PubMed ID: 27811854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
    Ogino S; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
    J Mol Diagn; 2006 Nov; 8(5):582-8. PubMed ID: 17065427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.
    Kim CH; Huh JW; Kim HR; Kim YJ
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer.
    de Vogel S; Wouters KA; Gottschalk RW; van Schooten FJ; de Goeij AF; de Bruïne AP; Goldbohm RA; van den Brandt PA; Weijenberg MP; van Engeland M
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3086-96. PubMed ID: 19843671
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of the CpG island methylator phenotype on survival outcome in colon cancer.
    Kang KJ; Min BH; Ryu KJ; Kim KM; Chang DK; Kim JJ; Rhee JC; Kim YH
    Gut Liver; 2015 Mar; 9(2):202-7. PubMed ID: 25167802
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype.
    Tricarico R; Madzo J; Scher G; Cohen M; Jelinek J; Maegawa S; Nagarathinam R; Scher C; Chang WC; Nicolas E; Slifker M; Zhou Y; Devarajan K; Cai KQ; Kwok T; Nakajima P; Xu J; Mancuso P; Doneddu V; Bagella L; Williams R; Balachandran S; Maskalenko N; Campbell K; Ma X; Cañadas I; Viana-Errasti J; Moreno V; Valle L; Grivennikov S; Peshkova I; Kurilenko N; Mazitova A; Koltsova E; Lee H; Walsh M; Duttweiler R; Whetstine JR; Yen TJ; Issa JP; Bellacosa A
    Gastroenterology; 2023 May; 164(6):921-936.e1. PubMed ID: 36764492
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aberrant DNA methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the CpG island methylator phenotype.
    Gebhard C; Mulet-Lazaro R; Glatz D; Schwarzfischer-Pfeilschifter L; Schirmacher P; Gaedcke J; Weichert W; Reuschel E; Dietmaier W; Rehli M
    Int J Cancer; 2022 Feb; 150(4):617-625. PubMed ID: 34591983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.
    Fu T; Pappou EP; Guzzetta AA; Jeschke J; Kwak R; Dave P; Hooker CM; Morgan R; Baylin SB; Iacobuzio-Donahue CA; Wolfgang CL; Ahuja N
    Clin Cancer Res; 2012 Sep; 18(17):4743-52. PubMed ID: 22825585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
    Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
    Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.